Imagen de Portada

Allostatic load dynamics, Alzheimer's disease biomarkers, and progression in individuals with mild cognitive impairment: findings from the Alzheimer's Disease Neuroimaging Initiative

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Juliana N. Souza‐Talarico, Yelena Perkhounkova, Maria Hein, Jihye Lee, Marco Hefti, Shireen Sindi
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Excessive sleep is associated with worse cognition, cognitive decline, and dementia in mild cognitive impairment
por: Marieclaire Overton, et al.
Publicado: (2025)

Retinal vascular biomarkers in mild cognitive impairment and Alzheimer's disease: a comprehensive review and meta‐analysis
por: Sunu Mathew, et al.
Publicado: (2025)

Longitudinal changes in the brain‐age gap in mild cognitive impairment and their relationships with neuropsychological functions and Alzheimer's disease biomarkers
por: Rachel R. Jin, et al.
Publicado: (2025)

Validation of regression‐based change formulae for mild cognitive impairment and Alzheimer's disease
por: Kevin Duff, et al.
Publicado: (2024)

Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?
por: María A. Rodríguez‐Santiago, et al.
Publicado: (2024)

Utilizing deep learning to predict Alzheimer's disease and mild cognitive impairment with optical coherence tomography
por: Jacqueline Chua, et al.
Publicado: (2025)

Non‐Alzheimer's amnestic mild cognitive impairment with medial temporal hypometabolism
por: Sebastiaan De Keersmaecker, et al.
Publicado: (2024)

Alzheimer's disease cerebrospinal fluid biomarkers and kidney function in normal and cognitively impaired older adults
por: Ihab Hajjar, et al.
Publicado: (2024)

Eye tracking as a diagnostic tool in Alzheimer's disease, mild cognitive impairment, and related dementias: a systematic review
por: Gustavo Luis Verón, et al.
Publicado: (2025)

Real‐world use of diagnostic tests for mild cognitive impairment, Alzheimer's disease, and other dementias in Medicare fee‐for‐service beneficiaries
por: Jessie T. Yan, et al.
Publicado: (2025)

Task‐evoked pupillary responses as potential biomarkers of mild cognitive impairment
por: Julius Opwonya, et al.
Publicado: (2024)

Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
por: Sofia Toniolo, et al.
Publicado: (2024)

Tracking clinical and neuroimaging progression of Alzheimer's disease by longitudinal trajectories of plasma biomarkers
por: Frederikke Kragh Clemmensen, et al.
Publicado: (2026)

Divergent effects of age on imaging‐based ATN biomarkers and cognition in Alzheimer's disease
por: Lars Frings, et al.
Publicado: (2025)

Criterion and convergent validity of plasma biomarkers in early‐onset Alzheimer's disease: Initial findings from LEADS
por: Dustin B. Hammers, et al.
Publicado: (2026)

Associations of plasma phosphorylated tau217 with cognitive impairment and brain microstructural alterations in Alzheimer's disease
por: Miguel Ángel Rivas‐Fernández, et al.
Publicado: (2026)

Omega‐3 blood biomarkers relate to brain glucose uptake in individuals at risk of Alzheimer's disease dementia
por: Iolanda Lázaro, et al.
Publicado: (2024)

Rest‐activity rhythm characteristics associated with lower cognitive performance and Alzheimer's disease biomarkers in midlife women
por: Alexandra Paget‐Blanc, et al.
Publicado: (2025)

Association between BrainAGE and Alzheimer's disease biomarkers
por: Yousaf Abughofah, et al.
Publicado: (2025)

General practitioners’ perspectives on blood biomarkers for Alzheimer's disease
por: Thomas Claessen, et al.
Publicado: (2025)

Plasma amyloid‐β oligomerization tendency as a potential predictor for conversion from mild cognitive impairment to Alzheimer's dementia: Findings from the GMCII cohort
por: Yuhan Xie, et al.
Publicado: (2025)

Prevalence and predictors of diagnosed mild cognitive impairment among Medicare beneficiaries
por: Elyse Couch, et al.
Publicado: (2025)

The prognosis of mild cognitive impairment: A systematic review and meta‐analysis
por: Simone Salemme, et al.
Publicado: (2025)

Caregivers’ attitudes toward blood‐based biomarker testing for Alzheimer's disease
por: Katharina Bolsewig, et al.
Publicado: (2024)

Poor dream recall associates with Alzheimer's disease biomarkers and dementia risk
por: Darren M. Lipnicki, et al.
Publicado: (2026)

Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease
por: Soheil Mohammadi, et al.
Publicado: (2025)

Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting
por: Steffi De Meyer, et al.
Publicado: (2025)

Alzheimer's disease neuropathology and longitudinal change in subjective cognitive complaints
por: Alisa Bannerjee, et al.
Publicado: (2025)

A systematic review and meta‐analysis of basal microbiota and cognitive function in Alzheimer's disease: A potential target for treatment or a contributor to disease progression?
por: Ana Maria Jimenez‐García, et al.
Publicado: (2024)

Correction to “The prognosis of mild cognitive impairment: A systematic review and meta‐analysis”
Publicado: (2025)

Risk prediction of mild cognitive impairment using electronic health record data
por: Gang Li, et al.
Publicado: (2025)

The relative contribution of modifiable and non‐modifiable factors for determining cognition in mid‐life individuals at risk for late‐life Alzheimer's disease
por: Bolin Cao, et al.
Publicado: (2026)

Clinical performance of the fully automated Lumipulse plasma p‐tau217 assay in mild cognitive impairment and mild dementia
por: Adam H. Dyer, et al.
Publicado: (2025)

Clinical classification of memory and cognitive impairment with multimodal digital biomarkers
por: Russell Banks, et al.
Publicado: (2024)

Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome
por: Emily K. Schworer, et al.
Publicado: (2024)

Plasma lipid metabolites as biomarkers of early white matter degeneration in Alzheimer's disease
por: Alireza Shaabanpoor Haghighi, et al.
Publicado: (2025)

Web‐based LAS‐FNAME and blood biomarkers in autosomal dominant Alzheimer's disease
por: Christopher Gonzalez Corona, et al.
Publicado: (2026)

How can Alzheimer's disease blood‐based biomarkers reach clinical practice?
por: Robert Perneczky, et al.
Publicado: (2025)

Application of machine learning to blood‐based biomarkers of Alzheimer's disease in Down syndrome
por: Patrick H. Luckett, et al.
Publicado: (2026)

Amyloid accumulation, brain atrophy, and cognitive decline in emergent Alzheimer's disease
por: Ying Xia, et al.
Publicado: (2025)